DHG Pharmaceutical Joint Stock Company

HOSE:DHG Stock Report

Market Cap: ₫13.4t

DHG Pharmaceutical Past Earnings Performance

Past criteria checks 2/6

DHG Pharmaceutical has been growing earnings at an average annual rate of 9%, while the Pharmaceuticals industry saw earnings growing at 8.3% annually. Revenues have been growing at an average rate of 6.7% per year. DHG Pharmaceutical's return on equity is 18.8%, and it has net margins of 16.2%.

Key information

9.0%

Earnings growth rate

9.0%

EPS growth rate

Pharmaceuticals Industry Growth13.0%
Revenue growth rate6.7%
Return on equity18.8%
Net Margin16.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How DHG Pharmaceutical makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

HOSE:DHG Revenue, expenses and earnings (VND Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 244,960,915804,0861,257,7990
30 Jun 244,998,538814,1461,301,6650
31 Mar 245,045,356884,6961,315,1930
31 Dec 235,015,3951,017,1431,291,2640
30 Sep 234,810,958993,7751,270,0140
30 Jun 234,873,1821,090,0861,220,6340
31 Mar 234,839,7991,058,4311,210,4540
31 Dec 224,676,016956,8011,181,4170
30 Sep 224,439,228892,0711,174,9160
30 Jun 224,221,993830,9931,122,4640
31 Mar 224,050,562798,3231,061,8580
31 Dec 214,003,170747,9031,060,1270
30 Sep 214,121,504787,0631,023,8780
30 Jun 214,042,091752,087998,9940
31 Mar 213,914,547737,784994,1760
31 Dec 203,755,619711,6791,002,1600
30 Sep 203,823,169706,7501,020,0920
30 Jun 203,832,489658,0891,043,5560
31 Mar 203,988,019649,9481,064,3070
31 Dec 193,896,754610,3261,020,8750
30 Sep 193,829,823593,6461,003,3920
30 Jun 193,783,556614,656997,7890
31 Mar 193,740,890568,033995,8140
31 Dec 183,882,128581,9211,010,5220
30 Sep 184,022,342529,2461,019,5510
30 Jun 184,096,274513,6251,047,5860
31 Mar 184,088,815553,9231,033,7750
31 Dec 174,062,753572,3581,050,4710
30 Sep 173,885,199626,5901,005,5420
30 Jun 173,899,974643,271969,7920
31 Mar 173,849,999605,147947,8170
31 Dec 163,783,045585,715928,9580
30 Sep 163,756,702521,875886,2090
30 Jun 163,830,975528,813821,9830
31 Mar 163,754,089539,435761,8200
31 Dec 153,607,760500,418719,9240
30 Sep 153,770,063468,2011,028,0830
30 Jun 153,687,376446,7031,178,2300
31 Mar 153,857,620429,4491,342,6170
31 Dec 143,912,518450,4841,411,3630
30 Sep 143,691,476501,7171,207,1520
30 Jun 143,589,442585,4001,142,6200
31 Mar 143,344,391591,1971,052,5120

Quality Earnings: DHG has high quality earnings.

Growing Profit Margin: DHG's current net profit margins (16.2%) are lower than last year (20.7%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: DHG's earnings have grown by 9% per year over the past 5 years.

Accelerating Growth: DHG's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: DHG had negative earnings growth (-19.1%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13%).

Return on Equity

High ROE: DHG's Return on Equity (18.8%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/10 18:11
End of Day Share Price 2025/01/10 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

DHG Pharmaceutical Joint Stock Company is covered by 9 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hang Thi VuCGS International
Kien GiangFPT Securities
Michael KokalariMaybank Investment Bank Berhad